Thursday, 13. December 2018 | Filed under Company News

Company News: Curetis Sharpens Focus on Near-Term Strategic Value Drivers

— Business focus on U.S. commercialization, strategic partnering, Ares Genetics and asset monetization

— Reduction of net cash consumption by up to 50% (YoY) expected

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced an update on its strategic value creation priorities for 2019 and beyond. Read more…

Thursday, 13. December 2018 | Filed under Company News

Company News: Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine

— The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability

— Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible

Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study of the second-generation COP allergy vaccines based on its research collaboration with Mymetics SA, a leader in the research and development of virosome-based vaccines. Read more…

Tuesday, 11. December 2018 | Filed under Company News

Company News: Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for the Treatment of Chronic Heart Failure

— Collaboration with Hannover Medical School (MHH)

Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH). Read more…